Show simple item record

dc.contributor.authorCampana, Luca G
dc.contributor.authorPeric, B.
dc.contributor.authorMascherini, M.
dc.contributor.authorSpina, R.
dc.contributor.authorKunte, C.
dc.contributor.authorKis, E.
dc.contributor.authorRozsa, P.
dc.contributor.authorQuaglino, P.
dc.contributor.authorJones, R. P.
dc.contributor.authorClover, A. J. P.
dc.contributor.authorCuratolo, P.
dc.contributor.authorGiorgione, R.
dc.contributor.authorCemazar, M.
dc.contributor.authorTerlizzi, F.
dc.contributor.authorBosnjak, M.
dc.contributor.authorSersa, G.
dc.date.accessioned2021-09-30T11:56:03Z
dc.date.available2021-09-30T11:56:03Z
dc.date.issued2021en
dc.identifier.citationCampana LG, Peric B, Mascherini M, Spina R, Kunte C, Kis E, et al. Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry. Cancers. 2021 Aug 25;13(17):4289.en
dc.identifier.pmid34503099en
dc.identifier.doi10.3390/cancers13174289en
dc.identifier.urihttp://hdl.handle.net/10541/624603
dc.description.abstractElectrochemotherapy (ECT) is an effective locoregional therapy for cutaneous melanoma metastases and has been safely combined with immune checkpoint inhibitors in preliminary experiences. Since ECT is known to induce immunogenic cell death, its combination with immune checkpoint inhibitors might be beneficial. In this study, we aimed to investigate the effectiveness of ECT on cutaneous melanoma metastases in combination with pembrolizumab. We undertook a retrospective matched cohort analysis of stage IIIC-IV melanoma patients, included in the International Network for sharing practices of ECT (InspECT) and the Slovenian Cancer Registry. We compared the outcome of patients who received the following treatments: (a) pembrolizumab alone, (b) pembrolizumab plus ECT, and (c) ECT. The groups were matched for age, sex, performance status, and size of skin metastases. The local objective response rate (ORR) was higher in the pembrolizumab-ECT group than in the pembrolizumab group (78% and 39%, p < 0.001). The 1 year local progression-free survival (LPFS) rates were 86% and 51% (p < 0.001), and the 1 year systemic PFS rates were 64% and 39%, respectively (p = 0.034). The 1 year overall survival (OS) rates were 88% and 64%, respectively (p = 0.006). Our results suggest that skin-directed therapy with ECT improves superficial tumor control in melanoma patients treated with pembrolizumab. Interestingly, we observed longer PFS and OS in the pembrolizumab-ECT group than in the pembrolizumab group. These findings warrant prospective confirmation.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3390/cancers13174289en
dc.titleCombination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma: a comparative retrospective study from the InspECT and Slovenian Cancer Registryen
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, The Christie NHS Foundation Trust, Manchester M20 4BX, UKen
dc.identifier.journalCancersen
dc.description.noteen]
refterms.dateFOA2021-10-13T08:21:00Z


Files in this item

Thumbnail
Name:
34503099.pdf
Size:
693.7Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record